ProActive Capital Group Announces Roster of Clients Presenting at 16th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 3, 2014 (GLOBE NEWSWIRE) -- ProActive Capital Group, a leading capital markets advisory and media strategies firm, announces a client roster of fourteen presenting companies at the 2014 Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference will be held at The New York Palace Hotel on September 9th and 10th, 2014.

More than 200 public & private companies from around the world are expected to present to an audience of over 1,500 attendees. The conference will feature tracks devoted to Biotechnology/Healthcare, Technology, Natural Resources, and Growth companies. The Conference will include corporate presentations and Q & A sessions, investor one-on-one meetings and daily networking opportunities.

To visit the conference website click here:

In addition, if you are interested in meeting with any of these companies, please contact Adam Holdsworth or Jared Mitchell at ProActive Capital Group – 646-862-4607.

These companies will provide an overview of each of their businesses during a live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. The list of ProActive Capital's clients include:

  • Soligenix, Inc. (SNGX): A clinical stage biopharmaceutical company focused on developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.

Presenting at 1:15 pm on Monday the 9th

  • Cesca Therapeutics, Inc. (KOOL): A leading designer and supplier of clinical technologies for processing, storage and administration of stem cells used in the practice of regenerative medicine.

Presenting at 1:40 pm on Monday the 9th

  • Celator Pharmaceuticals, Inc. (CPXX): A leader in the development of advanced therapies of treat cancer using their Combiplex technology novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit and locks the desired ratio in a nano-scale drug delivery vehicle.

Presenting at 2:05 pm on Monday the 9th

  • GeoVax Labs, Inc. (GOVX): A biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency).

Presenting at 3:20 pm on Monday the 9th

  • Æterna Zentaris, Inc. (AEZS): A biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs.

Presenting at 3:20 pm on Monday the 9th

  • Arch Theraputics, Inc. (ARTH): A medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care.

Presenting at 4:10 pm on Monday the 9th

  • Inovio Pharmaceuticals, Inc. (INO): Revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases.

Presenting at 10:25 am on Tuesday the 10th

  • Stevia First Corporation (STVF): An agricultural biotechnology company focused initially on stevia, using proprietary fermentation methods combined with modern U.S. agricultural innovations.

Presenting at 10:50 am on Tuesday the 10th

  • Calpian, Inc. (CLPI): A global mobile payments technology and processing company offering mobile payment services through Indian subsidiary Money-On-Mobile and domestic transaction services through Calpian Commerce.

Presenting at 11:40 am on Tuesday the 10th

  • Actinium Pharmaceuticals, Inc. (ATNM):A biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.

Presenting at 1:40 pm on Tuesday the 10th

  • Anavex Life Sciences Corp. (AVXL): A clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other CNS diseases and various types of cancer.

Presenting at 1:40 pm on Tuesday the 10th

  • Boston Therapeutics, Inc. (BTHE): A pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes.

Presenting at 2:55 pm on Tuesday the 10th

  • Lixte Biotechnology Holdings, Inc. (LIXT): A clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer.

Presenting at 3:45 pm on Tuesday the 10th

  • WaferGen Bio-systems, Inc. (WGBS): An emerging leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries.

Presenting at 4:10 pm on Tuesday the 10th

About ProActive Capital Group

ProActive Capital Group is dedicated to the discovery and creation of value specifically in the emerging public company marketplace. The Company provides unique solutions that combine capital markets advisory and strategic communications. PCG's overarching goal is to develop and leverage stakeholder awareness from all key constituents in order to maximize shareholder value. PCG's capital markets advisory services include overall investor strategy development to increase and leverage awareness, visibility & credibility. The Company's strategic communications services leverage traditional, digital and social media channels to further increase awareness to all key constituents. Communicating the client's story accurately and effectively to a wide but concentrated audience is tantamount to maximizing exposure to its current and potential stakeholders. For additional information:

About Rodman & Renshaw Conferences, LLC

The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

CONTACT: Adam Holdsworth ProActive Capital Group 646-862-4607 adamh@proactivecapital.comSource:ProActive Capital